312 related articles for article (PubMed ID: 22085233)
1. Cardiovascular comorbidity and treatment regret in men with recurrent prostate cancer.
Nguyen PL; Chen MH; Hoffman KE; Chen RC; Hu JC; Bennett CL; Kattan MW; Sartor O; Stein K; D'Amico AV
BJU Int; 2012 Jul; 110(2):201-5. PubMed ID: 22085233
[TBL] [Abstract][Full Text] [Related]
2. Radical prostatectomy vs radiation therapy and androgen-suppression therapy in high-risk prostate cancer.
Westover K; Chen MH; Moul J; Robertson C; Polascik T; Dosoretz D; Katin M; Salenius S; D'Amico AV
BJU Int; 2012 Oct; 110(8):1116-21. PubMed ID: 22540922
[TBL] [Abstract][Full Text] [Related]
3. Regret in men treated for localized prostate cancer.
Hu JC; Kwan L; Saigal CS; Litwin MS
J Urol; 2003 Jun; 169(6):2279-83. PubMed ID: 12771770
[TBL] [Abstract][Full Text] [Related]
4. Predictors of the use of supplemental androgen suppression therapy and external beam radiation in men with high-risk prostate cancer undergoing brachytherapy in community practice.
Hattangadi JA; Chen MH; Braccioforte MH; Moran BJ; D'Amico AV
Brachytherapy; 2011; 10(5):369-75. PubMed ID: 21349778
[TBL] [Abstract][Full Text] [Related]
5. Determinants of treatment regret in low-income, uninsured men with prostate cancer.
Hu JC; Kwan L; Krupski TL; Anger JT; Maliski SL; Connor S; Litwin MS
Urology; 2008 Dec; 72(6):1274-9. PubMed ID: 18313115
[TBL] [Abstract][Full Text] [Related]
6. Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality.
Tsai HK; D'Amico AV; Sadetsky N; Chen MH; Carroll PR
J Natl Cancer Inst; 2007 Oct; 99(20):1516-24. PubMed ID: 17925537
[TBL] [Abstract][Full Text] [Related]
7. The association between race and treatment regret among men with recurrent prostate cancer.
Mahal BA; Chen MH; Bennett CL; Kattan MW; Sartor O; Stein K; D'Amico AV; Nguyen PL
Prostate Cancer Prostatic Dis; 2015 Mar; 18(1):38-42. PubMed ID: 25348256
[TBL] [Abstract][Full Text] [Related]
8. Factors associated with treatment received by men diagnosed with prostate cancer in Queensland, Australia.
Baade PD; Youlden DR; Gardiner RA; Ferguson M; Aitken JF; Yaxley J; Chambers SK
BJU Int; 2012 Dec; 110(11 Pt B):E712-9. PubMed ID: 23017157
[TBL] [Abstract][Full Text] [Related]
9. Fear of cancer recurrence in patients undergoing definitive treatment for prostate cancer: results from CaPSURE.
Mehta SS; Lubeck D; Pasta DJ; Litwin MS
J Urol; 2003 Nov; 170(5):1931-3. PubMed ID: 14532810
[TBL] [Abstract][Full Text] [Related]
10. Predictors of prostate cancer-specific mortality in elderly men with intermediate-risk prostate cancer treated with brachytherapy with or without external beam radiation therapy.
Nanda A; Chen MH; Moran BJ; Braccioforte MH; Dosoretz D; Salenius S; Katin M; Ross R; D'Amico AV
Int J Radiat Oncol Biol Phys; 2010 May; 77(1):147-52. PubMed ID: 19744800
[TBL] [Abstract][Full Text] [Related]
11. Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE).
Kawakami J; Cowan JE; Elkin EP; Latini DM; DuChane J; Carroll PR;
Cancer; 2006 Apr; 106(8):1708-14. PubMed ID: 16544313
[TBL] [Abstract][Full Text] [Related]
12. Influence of body mass index on prostate-specific antigen failure after androgen suppression and radiation therapy for localized prostate cancer.
Efstathiou JA; Chen MH; Renshaw AA; Loffredo MJ; D'Amico AV
Cancer; 2007 Apr; 109(8):1493-8. PubMed ID: 17340594
[TBL] [Abstract][Full Text] [Related]
13. Prostate cancer-specific mortality and the extent of therapy in healthy elderly men with high-risk prostate cancer.
Hoffman KE; Chen MH; Moran BJ; Braccioforte MH; Dosoretz D; Salenius S; Katin MJ; Ross R; D'Amico AV
Cancer; 2010 Jun; 116(11):2590-5. PubMed ID: 20310055
[TBL] [Abstract][Full Text] [Related]
14. Cardiovascular comorbidity and mortality in men with prostate cancer treated with brachytherapy-based radiation with or without hormonal therapy.
Nanda A; Chen MH; Moran BJ; Braccioforte MH; D'Amico AV
Int J Radiat Oncol Biol Phys; 2013 Apr; 85(5):e209-15. PubMed ID: 23332383
[TBL] [Abstract][Full Text] [Related]
15. Surgical management after active surveillance for low-risk prostate cancer: pathological outcomes compared with men undergoing immediate treatment.
Dall'Era MA; Cowan JE; Simko J; Shinohara K; Davies B; Konety BR; Meng MV; Perez N; Greene K; Carroll PR
BJU Int; 2011 Apr; 107(8):1232-7. PubMed ID: 20804478
[TBL] [Abstract][Full Text] [Related]
16. Predictors of secondary cancer treatment in patients receiving local therapy for prostate cancer: data from cancer of the prostate strategic urologic research endeavor.
Grossfeld GD; Li YP; Lubeck DP; Broering JM; Mehta SS; Carroll PR
J Urol; 2002 Aug; 168(2):530-5. PubMed ID: 12131303
[TBL] [Abstract][Full Text] [Related]
17. Age, body mass index, and serum prostate-specific antigen correlate with bone loss in men with prostate cancer not receiving androgen deprivation therapy.
Conde FA; Sarna L; Oka RK; Vredevoe DL; Rettig MB; Aronson WJ
Urology; 2004 Aug; 64(2):335-40. PubMed ID: 15302490
[TBL] [Abstract][Full Text] [Related]
18. Bowel function and bother after treatment for early stage prostate cancer: a longitudinal quality of life analysis from CaPSURE.
Litwin MS; Sadetsky N; Pasta DJ; Lubeck DP
J Urol; 2004 Aug; 172(2):515-9. PubMed ID: 15247718
[TBL] [Abstract][Full Text] [Related]
19. Predictors of fatigue after treatment for prostate cancer.
Maliski SL; Kwan L; Orecklin JR; Saigal CS; Litwin MS
Urology; 2005 Jan; 65(1):101-8. PubMed ID: 15667873
[TBL] [Abstract][Full Text] [Related]
20. Health-related quality of life and satisfaction with care among older men treated for prostate cancer with either radical prostatectomy or external beam radiation therapy.
Jayadevappa R; Chhatre S; Whittington R; Bloom BS; Wein AJ; Malkowicz SB
BJU Int; 2006 May; 97(5):955-62. PubMed ID: 16643477
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
